Search QAs

Are manufacturers of insurance products expected to apply the Product Oversight and Governance requirements with regard to insurance products which are distributed by ancillary insurance intermediaries exempted from the scope of the IDD?

How can the manufacturer demonstrate that they have taken into account the level of information available to customers and the financial literacy of customers?

Can EIOPA provide more guidance on how to assess the granularity of the target market?

For investments in private equity funds there is normally not possible to report Quantity in C0130, S.06.02 List of assets. Can it be wise to report just 1.0 in C0130/Quantity or should the cell be left empty?

Legal environment:
According to the balance sheet instructions of Implementing Regulation 2015/2450 the item "Deposits from reinsurers" reflects "amounts (e.g. cash) received from Reinsurer or deducted by the reinsurer according to reinsurance contract".

When a company sells equity there will be a short term cash receivable during the time the shares been sold but the settlement for cash is not made. In the balance sheet S.02.01 it will be reported in R0420/ Any other assets, not elsewhere shown. In S.06.02 List of assets. Our view is that the...

How is the target market identified in practice if the insurance product is required by law?

Is it necessary to draw up and provide a PRIIPs KID in relation to a multi-option insurance-based investment product that is closed to new investment, but for which new underlying investment options are made available to existing investors, that were not available prior to 1 January 2018?

Can the qualification process be performed AFTER the investment was made?